We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Regeneron Wins Expanded Eylea Approval for CRVO
Regeneron Wins Expanded Eylea Approval for CRVO
September 21, 2012
The FDA Friday approved a second indication for Regeneron Pharmaceuticals’ Eylea to treat macular edema following central retinal vein occlusion (CRVO).